Sökning: onr:"swepub:oai:DiVA.org:liu-50326" > Prevention of chemo...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05245naa a2200625 4500 | |
001 | oai:DiVA.org:liu-50326 | |
003 | SwePub | |
008 | 091011s2006 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-503262 URI |
024 | 7 | a https://doi.org/10.1093/annonc/mdj0782 DOI |
040 | a (SwePub)liu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a for2 swepub-publicationtype |
100 | 1 | a Roila, F.u Medical Oncology Division, Silvestrini Hospital, 06156S Andrea delle Fratte, Perugia, Italy4 aut |
245 | 1 0 | a Prevention of chemotherapy- and radiotherapy-induced emesis :b Results of the 2004 Perugia International Antiemetic Consensus Conference |
264 | 1 | b Elsevier BV,c 2006 |
338 | a print2 rdacarrier | |
520 | a Background: In the late 1990s, several professional organizations convened antiemetic guideline groups and published the findings of these expert panels. Each of these documents was based on analyses of the available published trials and provided nearly similar recommendations. Nonetheless, small differences in emetic risk categories and treatment recommendations led to confusion in antiemetics selection. With the emergence of new findings and agents since the guidelines were initially published, many of the oncology professional societies have updated the antiemetic guidelines. Materials and methods: A literature review up to March 2004 was carried out using MEDLINE with evaluation of the evidence by an expert panel composed of 23 oncology professionals in clinical medicine, medical oncology, radiation oncology, oncology nursing, statistics, pharmacy, medical policy and decision making, and pharmacology. The experts represented nine oncology professional societies and came from 11 different countries on four continents. Results: Recommendations on antiemetic regimens to prevent emesis induced by high, moderate, low and minimal risk chemotherapy were suggested as well as management of anticipatory emesis. Furthermore, recommendations for refractory emesis, emesis induced by high-dose chemotherapy and radiotherapy and for antiemetics in children receiving chemotherapy were elaborated. Conclusions: Recommendations about antiemetic prophylaxis in patients receiving treatment with chemo- and radiotherapy have been updated by representatives of nine oncological organizations. © 2005 European Society for Medical Oncology. | |
653 | a 5-HT3-receptor antagonists | |
653 | a Acute emesis | |
653 | a Aprepitant | |
653 | a Delayed emesis | |
653 | a Dexamethasone | |
653 | a Metoclopramide | |
653 | a NATURAL SCIENCES | |
653 | a NATURVETENSKAP | |
700 | 1 | a Aapro, M.u Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland4 aut |
700 | 1 | a Ballatori, E.u Statistics Unit, L'Aquila, Italy4 aut |
700 | 1 | a Borjeson, S.u Division of Nursing Science, Linkoping University, Linkoping, Sweden4 aut |
700 | 1 | a Clark-Snow, R.A.u University of Kansas Cancer Center, Kansas City, KS, United States4 aut |
700 | 1 | a Del, Favero A.u Del Favero, A., Department of Internal Medicine and Oncological Sciences, Perugia, Italy4 aut |
700 | 1 | a Einhorn, L.H.u Walther Cancer Institute, Indianapolis, IN, United States4 aut |
700 | 1 | a Feyer, P.u Viventes Clinics Berlin-Neukölln, Berlin, Germany4 aut |
700 | 1 | a Gralla, R.J.u New York Lung Cancer Alliance, New York, NY, United States4 aut |
700 | 1 | a Grunberg, S.M.u University of Vermont, Burlington, VT, United States4 aut |
700 | 1 | a Herrstedt, J.u Copenhagen University Hospital, Copenhagen, Denmark4 aut |
700 | 1 | a Hesketh, P.J.u Caritas St. Elizabeth's Medical Center, Boston, MA, United States4 aut |
700 | 1 | a Kaiser, R.u University Clinic, Goettingen, Germany4 aut |
700 | 1 | a Koeller, J.u University of Texas Health Science Center, San Antonio, TX, United States4 aut |
700 | 1 | a Kris, M.G.u Memorial Sloan-Kettering Cancer Center, New York, NY, United States4 aut |
700 | 1 | a Maranzano, E.u Radiation Oncology Center, 'S.S. Maria' Hospital, Terni, Italy4 aut |
700 | 1 | a Molassiotis, A.u School of Nursing, University of Manchester, Manchester, United Kingdom4 aut |
700 | 1 | a Olver, I.u Royal Adelaide Hospital Cancer Center, Adelaide, SA, Australia4 aut |
700 | 1 | a Osoba, D.u QOL Consulting, West Vancouver, BC, Canada4 aut |
700 | 1 | a Rapoport, B.L.u The Medical Oncology Centre of Rosebank, Johannesburg, South Africa4 aut |
700 | 1 | a Rittenberg, C.u Rittenberg Oncology Consulting, Metaire, LA, United States4 aut |
700 | 1 | a Tonato, M.u Perugia Regional Cancer Center, Perugia, Italy4 aut |
700 | 1 | a Warr, D.u Princess Margaret Hospital, University of Toronto, Toronto, Ont., Canada4 aut |
710 | 2 | a Medical Oncology Division, Silvestrini Hospital, 06156S Andrea delle Fratte, Perugia, Italyb Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland4 org |
773 | 0 | t Annals of Oncologyd : Elsevier BVg 17:1, s. 20-28q 17:1<20-28x 0923-7534x 1569-8041 |
856 | 4 | u https://doi.org/10.1093/annonc/mdj078 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-50326 |
856 | 4 8 | u https://doi.org/10.1093/annonc/mdj078 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.